Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Analyst Reports
3-Feb-2022
Maxim Group: Studies on Track, Cash through YE22
7-Dec-2021
H.C. Wainwright & Co. - Phase 2 In Line With Expectations; A Catalyst-Rich 2022
6-Dec-2021
Bell Potter - Headline Data - 3 Month Survival Benefit
3-Dec-2021
Maxim Group: Final P2 Paxalisib Data Largely Incremental; More Pax Data in 2022
14-Oct-2021
Maxim Group: Equity Research Initiation on Kazia
13-Oct-2021
Edison Research: Multiple paxalisib data points expected in Q4
10-May-2021
Bell Potter: Kazia Therapeutics - New In-license deal
21-Apr-2021
Corporate Connect: Another Deal – Kazia Inlicences New Anti-Cancer Med From Highly Impressive Partner
21-Apr-2021
H.C. Wainwright: Expanding Pipeline With EVT801 In-License; Reiterate Buy
20-Apr-2021
Edison Research: New asset to target tumor lymphangiogenesis
30-Mar-2021
Bell Potter: Kazia Therapeutics - China Out License Deal
2-Mar-2021
Corporate Connect: Cantrixil licensed To Oasmia Pharmaceuticals & Kazia Shareholders Learn a Positive Lesson About Kazia
2-Mar-2021
Edison Research: All in on GBM AGILE, but eyes on brain mets
5-Jan-2021
HC Wainwright: A Unique PI3K Inhibitor for Brain Tumors; Initiate With Buy and $17 PT
15-Dec-2020
Bell Potter: Kazia Therapeutics - Paxalisib Joins A Second Platform Study
11-Dec-2020
Cantrixil final Phase I data reported (ADR update)
10-Dec-2020
Edison Research: Cantrixil final Phase I data reported
2-Dec-2020
Edison Research: Phase IIa shows good safety, consistent efficacy (ADR update)
25-Nov-2020
Edison Research: Phase IIa shows good safety, consistent efficacy
18-Nov-2020
Corporate Connect: Kazia Therapeutics - SNO Presentations: Late-Interim Results from Phase II GBM & Phase I DIPG Studies Released
18-Nov-2020
Bell Potter: Kazia Therapeutics (KZA) - Results Unlikely Due To Chance
2-Nov-2020
Bell Potter: Kazia Therapeutics - GBM Agile In More Detail
14-Oct-2020
Corporate Connect: Kazia Therapeutics - A Laser-Like Focus on Adding Value - 5 Data Readouts in 9-Months
12-Oct-2020
Bell Potter: Kazia Therapeutics - Approval Study Substantially Funded
27-Aug-2020
Bell Potter: Kazia Therapeutics - Strength To Strength
13-Aug-2020
Edison Research: Kazia Therapeutics - Bringing a vetted drug class to the brain
3-Jul-2020
Bell Potter: Kazia Therapeutics - 5 month survival extension
31-Mar-2020
Edison Research: Paxalisib trial still on track for H220 start
13-Jan-2020
Edison Research: An agile pivot
13-Jan-2020
Edison Research: An agile pivot (ADR Update)
2-Dec-2019
Edison Research: GDC-0084 – encouraging initial efficacy (ADR Update)
25-Nov-2019
Edison Research: GDC-0084 – encouraging initial efficacy
5-Sep-2019
Edison Research - GDC-0084 gets a fifth collaboration
23-Jun-2019
Edison Research - Higher MTD, new collaboration for GDC-0084
21-Jun-2019
Edison Research: Higher MTD, new collaboration for GDC-0084 (ADR Outlook)
1-Apr-2019
Edison Research: Cantrixil efficacy data presented at AACR (ADR Update)
1-Apr-2019
Edison Research - Cantrixil efficacy data presented at AACR
31-Oct-2018
Morgans interview with Kazia CEO Dr James Garner
31-Oct-2018
Edison Research - New indications for GDC-0084
29-Oct-2018
Edison Research: New indications for GDC-0084 (ADR Update)
24-Sep-2018
Edison Research - GDC-0084 and Cantrixil trials progressing
20-Sep-2018
Edison Research:GDC-0084 and Cantrixil trials progressing (ADR update)
14-May-2018
Edison Research - GDC-0084 Phase II underway
11-May-2018
Edison Research: GDC-0084 Phase II underway (ADR Outlook)
3-Apr-2018
NDF Research Re-initiates Research Coverage on Kazia Therapeutics
21-Dec-2017
Edison Research: GDC-0084 Phase II to begin shortly (ADR Update)
14-Dec-2017
Cedrus Investments - Kazia Therapeutics Targeting Unmet Oncological Needs
7-Nov-2017
NDF Research Initiates Research Coverage on Novogen
11-Sep-2017
Edison Research: GDC-0084 Phase II on track to commence Q417 (ADR Update)
11-Sep-2017
Edison Research - GDC-0084 Phase II on track to commence Q417
25-May-2017
Edison Research: Anisina nixed, GDC-0084 on track for Phase II (ADR Outlook)
22-May-2017
Edison research - Anisina nixed, GDC-0084 on track for Phase II
31-Oct-2016
Edison research – Novogen Acquires Mid-Stage Cancer Drug from Genentech
27-Sep-2016
H.C. Wainwright & Co Report – New Strategy in Place
11-May-2016
Edison Research: Cantrixil to enter clinic in H216 (ADR Update)
9-May-2016
Edison Report - Cantrixil to enter clinic in H216